1Siewert JR, Bottcher K, Stein H J, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-61.
2Iwanicki-Caron I, Di Fiore F, Roque I, et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008; 26: 3681-6.
3Ishigami S, Sakamoto A, Uenosono Y, et al. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J Surg Res 2008; 248: 205-9.
4Yamamoto M, Baba H, Toh Y, et al. Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 2007; 133: 471-6.
5Kim H J, Lee KW, Kim YJ, et al. Chemotherapy- induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Onco12009; 48: 385-90.
6Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients:a prospective clinical study. Gastric Cancer 2003; 6: 142-5.
7Kochi M, Fujii M, Kanamori N, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000; 3: 177-86.
8Ubukata H, Katano M, Motohashi G, et al. Evaluation of CA72-4 as a tumor marker in patients with gastric cancer. Gan To Kagaku Ryoho 2003; 30: 1821-4.
9Sheng SL, Wang Q, Huang G. Development of time-resolved immunofluorometric assays for CA 72-4 and application in sera of patients with gastric tumors. Clin Chim Acta 2007; 380: 106-11.
10Goral V, Yesilbagdan H, Kaplan A, et al. Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology 2007; 54: 1272-5.
